Rare diseases
Investigational molecules
Locations
A study to evaluate the effectiveness and safety of DT-101 in adults with major depressive disorder
CzechiaStudy of Maridebart Cafraglutide for Adults with Obstructive Sleep Apnea and Overweight or Obesity Who Use Positive Airway Pressure Therapy
CzechiaStudy of Revumenib, Cytarabine, and Fludarabine in Children with Relapsed or Refractory Acute Myeloid Leukemia
CzechiaStudy of Ziftomenib with drug combinations for adults with newly diagnosed acute myeloid leukemia with NPM1 or KMT2A genetic changes
CzechiaA Phase 3 Randomized, Double-blind,Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants with Obstructive Sleep Apnea not on Positive Airway Pressure Therapy and Living with Overweight or Obesity (MARITIME-OSA-2)
CzechiaN1T-MC-MALO: A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes (SYNERGY-Outcomes); N1T-MC-TZ01 Tirzepatide in participants with high-risk MASLD; N1T-MC-RT01 Retatrutide in participants with high-risk MASLD
CzechiaEvaluation of Long-Term Safety and Efficacy of Litifilimab in Adults with Active Systemic Lupus Erythematosus: A Phase 3 Multicenter, Randomized, Dose-Blind Study
CzechiaPhase 3 Evaluation of Etelcalcetide for Secondary Hyperparathyroidism in Pediatric Patients with Chronic Kidney Disease on Hemodialysis
CzechiaA study testing how well AZD4144 works and how safe it is for adults with acute kidney injury caused by sepsis
CzechiaA study comparing brelovitug to bulevirtide for treating chronic hepatitis delta infection in patients currently receiving bulevirtide
CzechiaA study of finerenone with standard treatment for children and young adults from birth to 18 years with heart failure and left ventricular systolic dysfunction
CzechiaA study of finerenone added to standard treatment in children aged 6 months to under 18 years with heart failure and reduced left heart pumping function
CzechiaTell us about your condition – we search every trial in Europe and connect you with the right site.
